月K · MACD · 年ROE Monthly Trend
MACD(12,26,9)
MACD · 前复权口径
年ROE(每份年报一根整柱,柱宽 = 生效期:报告期 + 4 个月起)
加载中…
获利能力 Profitability (单位:元)
| 指标 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025中报 | 2026中报 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 净资产收益率(ROE) | 43.51% | 40.83% | 38.88% | 41.35% | 39.58% | 24.08% | 22.21% | 26.30% | 30.24% | 35.74% | 38.07% | 26.25% | 13.09% | 26.43% | 15.91% | 11.35% | 10.60% |
| 扣非加权 ROE | 40.78% | 38.22% | 37.10% | 37.64% | 38.29% | 23.13% | 19.15% | 23.04% | 27.65% | 34.34% | 36.16% | 24.27% | 12.27% | 25.11% | 15.32% | 10.86% | 9.87% |
| 总资产收益率(ROA) | 30.77% | 29.28% | 27.46% | 29.69% | 29.11% | 15.55% | 16.71% | 19.59% | 22.88% | 27.21% | 24.88% | 16.42% | 7.87% | 15.24% | 9.85% | 7.40% | 7.35% |
| 毛利率 | 82.30% | 82.50% | 83.70% | 84.72% | 84.55% | 83.93% | 84.14% | 84.81% | 86.21% | 85.24% | 84.97% | 82.34% | 79.74% | 80.78% | 78.70% | 79.82% | 78.46% |
| 净利率 | 38.86% | 39.91% | 41.76% | 43.15% | 39.39% | 37.18% | 39.58% | 39.55% | 39.87% | 44.87% | 44.73% | 35.70% | 22.71% | 30.63% | 26.48% | 34.35% | 37.00% |
| 每股收益(EPS) | 0.58 | 0.27 | 0.34 | 0.43 | 0.54 | 0.52 | 0.69 | 0.97 | 0.72 | 1.10 | 1.49 | 1.12 | 0.55 | 1.05 | 0.69 | 0.51 | 0.49 |
财务结构 Financial Structure
| 指标 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025中报 | 2026中报 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 现金占总资产比率 | 71.18% | 63.63% | 53.79% | 43.20% | 41.74% | 58.47% | 62.36% | 52.67% | 50.98% | 48.97% | 48.22% | 47.24% | 50.70% | 32.04% | 46.51% | 14.19% | 11.49% |
| 负债占总资产比率 | 12.46% | 14.85% | 17.67% | 16.06% | 18.09% | 8.91% | 18.26% | 16.08% | 12.99% | 11.91% | 29.66% | 33.71% | 43.12% | 38.06% | 35.82% | 40.72% | 33.42% |
经营能力 Operating Capability
| 指标 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025中报 | 2026中报 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 应收账款周转率(次) | 29.11 | 32.83 | 27.82 | 10.08 | 9.77 | 7.21 | 6.76 | 7.99 | 9.05 | 11.65 | 9.94 | 11.24 | 25.68 | 50.09 | 68.75 | 45.32 | 22.45 |
| 平均收现日数 | 13 天 | 11 天 | 13 天 | 36 天 | 37 天 | 51 天 | 54 天 | 46 天 | 40 天 | 31 天 | 37 天 | 32 天 | 14 天 | 7 天 | 5 天 | 8 天 | 16 天 |
| 固定资产周转率(次) | 0.0437 | 0.0361 | 0.0303 | 0.2335 | 0.4985 | 0.4925 | 0.4529 | 0.4211 | 0.3827 | 0.3295 | 0.3555 | 0.4722 | 0.8499 | 0.6139 | 0.7969 | 1.4176 | 1.5177 |
| 总资产周转率 | 79.18% | 73.37% | 65.75% | 68.82% | 73.90% | 41.82% | 42.20% | 49.54% | 57.40% | 60.65% | 55.62% | 46.00% | 34.68% | 49.73% | 37.19% | 21.54% | 19.87% |
现金流量 Cash Flow (单位:亿元)
| 指标 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025中报 | 2026中报 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 现金及现金等价物 | 1.75 | 2.17 | 2.48 | 2.33 | 2.87 | 7.60 | 10.62 | 10.81 | 12.72 | 15.75 | 23.19 | 25.59 | 28.10 | 17.25 | 25.16 | 7.48 | 5.97 |
| 净利润 | 0.76 | 1.00 | 1.27 | 1.60 | 2.00 | 2.02 | 2.84 | 4.02 | 5.71 | 8.75 | 11.97 | 8.90 | 4.36 | 8.20 | 5.33 | 3.90 | 3.82 |
| 经营活动现金流量 | 0.77 | 1.20 | 1.33 | 1.37 | 2.05 | 1.79 | 3.04 | 3.84 | 5.83 | 9.57 | 12.49 | 8.84 | 9.17 | 10.51 | 7.21 | 5.38 | 4.11 |
| 投资活动现金流量 | -0.20 | -0.52 | -0.61 | -0.65 | -0.62 | -1.26 | -0.59 | -2.55 | -1.97 | -3.41 | -6.70 | -3.06 | -2.50 | -11.27 | 6.43 | -8.90 | -18.54 |
| 筹资活动现金流量 | 0.13 | -0.25 | -0.38 | -0.88 | -0.89 | 4.21 | 0.56 | -1.15 | -1.95 | -3.13 | 1.65 | -3.66 | -4.52 | -9.90 | -5.63 | -6.27 | -5.40 |
| 净现金流量 | 0.71 | 0.43 | 0.35 | -0.16 | 0.54 | 4.73 | 3.01 | 0.15 | 1.91 | 3.03 | 7.44 | 2.12 | 2.15 | -10.66 | 7.99 | -9.79 | -19.87 |
右侧两列为报告期累计口径同比(左:去年同期同一期次,右:最近一期季报,年报期次已在左侧列展示);周转率类指标为报告期累计值,未做年化。
医药生物
- 近五年ROE对比
1
41.25%
九安医疗
SZ002432
2
39.99%
小方制药
次新股
SH603207
3
37.78%
百迈科
数据<5年
次新股
BJ920268
4
31.92%
海昇药业
次新股
BJ920656
5
30.62%
迈瑞医疗
SZ300760
6
29.14%
特宝生物
SH688278
7
28.45%
安旭生物
SH688075
8
25.54%
百瑞吉
次新股
BJ920201
9
24.91%
博拓生物
SH688767
10
24.48%
惠泰医疗
SH688617
11
24.22%
百洋医药
SZ301015
12
24.07%
安杰思
SH688581
13
23.95%
健帆生物
SZ300529
14
23.64%
丹娜生物
次新股
BJ920009
15
22.86%
兴齐眼药
SZ300573
16
22.00%
片仔癀
SH600436
17
21.15%
新产业
SZ300832
18
21.04%
羚锐制药
SH600285
19
20.75%
健民集团
SH600976
20
20.52%
万邦医药
SZ301520
21
20.41%
西藏药业
SH600211
22
20.40%
九典制药
SZ300705
23
19.89%
心脉医疗
SH688016
24
19.80%
药明康德
SH603259
25
19.53%
瑞迈特
SZ301367
26
19.39%
达仁堂
SH600329
27
19.18%
阳光诺和
SH688621
28
19.16%
济川药业
SH600566
29
18.52%
三鑫医疗
SZ300453
30
18.51%
爱得科技
次新股
BJ920180